Conventional mammography, breast sonography and breast MRI have specific weaknesses. In particular, mammography has a low sensitivity for the detection of mammary carcinoma in patients with a dense breast. Phase contrast mammography could help to overcome some of these limitations. Observational study.
Category C2 Medicine product without CE label. Objective(s): Phase 0: Imaging of mastectomy and breast biopsy samples to validate the image quality and radiation dose. Phase 1: Determination of accurate radiation dose in vivo; dose exposure should remain within the range specified in the investigational brochure. Evaluation of cohort size for phase 2. Phase 2: Assessment of the diagnostic performance of phase contrast mammography compared to conventional digital mammography. Ouctomes: Sensitivity and specificity of phase contrast mammography compared to conventional digital mammography. Measurements and procedures: Phase 0: Phase contrast mammography of the mastectomy, tumorectomy or breast biopsy samples is performed after breast surgery in addition to the standard clinical procedures Phase 1: Phase contrast mammography is performed before the operation in case of known breast carcinoma in addition to the standard clinical procedures Phase 2: Phase contrast mammography is performed directly in the clinical routine. The result is compared with the result of the conventional digital mammography and the ultrasound examination. Number of Participants with Rationale: Phase 0: expected to be 30 Phase 1: expected to be 20 Phase 2: expected to be 300 (correct number will be defined according to Phase 1)
Study Type
OBSERVATIONAL
Enrollment
350
Mammography in the radiology department is commonly performed using General Electrics Medical Systems Senographe Essential device
University Hospital Zurich - Diagnostic Radiology
Zurich, Canton of Zurich, Switzerland
RECRUITINGUniversity of Zurich
Zurich, Switzerland
RECRUITINGSensitivity and specificity of PCM compared to FFDM represent the primary outcome since the limited sensitivity of mammography, in particular in patients with dense breasts, represents the major limitation of the currently applied FFDM.
The standard reference will be the histologic specimen after biopsy
Time frame: 30 month
Lesion extent will be estimated using both PCM and FFDM. Pathological measurements obtained from the surgical specimen will be used as standard of reference.
The aim is to evaluate if PCM, due to the expected improved visibility of the lesions, can allow for a better estimation of lesion extent with subsequent benefit on the preoperative planning.
Time frame: 30 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.